NICE recommends J&J's Imbruvica in MCL subgroup

The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Imbruvica ibrutinib from Johnson & Johnson (NYSE:JNJ) to treat mantle cell lymphoma (MCL) in patients who have had only one prior line of therapy -- a subgroup of its approved indication in the EU. The recommended dose of Imbruvica is four 140 mg capsules every day, and the list price is £6,132 ($8,201) for a 30-day supply of 120 capsules.

NICE previously recommended use of Imbruvica in the Cancer Drugs Fund (CDF) to treat Waldenstrom’s macroglobulinemia in patients treated with at least one prior therapy (see BioCentury, Dec. 8)...